{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:32Z","timestamp":1792788272971,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["K2014-65X-15320-10-3"],"award-info":[{"award-number":["K2014-65X-15320-10-3"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALF Stockholm Council"},{"name":"Westman"},{"DOI":"10.13039\/501100008035","name":"Njurfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0221-6","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T07:26:46Z","timestamp":1529911606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Hadi","family":"Molanaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rashid","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Heimb\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Diczfalusy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Anderstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8785-4820","authenticated-orcid":false,"given":"Peter","family":"Stenvinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"issue":"6","key":"221_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898\u2013903.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"221_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85(3):522\u20138.","journal-title":"Kidney Int"},{"issue":"5","key":"221_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1525-139X.2002.00083.x","volume":"15","author":"P Stenvinkel","year":"2002","unstructured":"Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15(5):329\u201337.","journal-title":"Semin Dial"},{"issue":"4","key":"221_CR4","doi-asserted-by":"publisher","first-page":"F938","DOI":"10.1152\/ajprenal.00256.2017","volume":"313","author":"J Kooman","year":"2017","unstructured":"Kooman J, Dekker M, Usvyat LA, Kotanko P, van der Sande F, Schalkwijk CG, Shiels P, Stenvinkel P. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol. 2017;313(4):F938\u201350.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"221_CR5","first-page":"207","volume":"29","author":"ET Morgan","year":"2001","unstructured":"Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29(3):207\u201312.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"221_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"221_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/dmd.107.018747","volume":"36","author":"ET Morgan","year":"2008","unstructured":"Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205\u201316.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"221_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/clpt.2014.143","volume":"96","author":"RD Harvey","year":"2014","unstructured":"Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96(4):449\u201357.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"221_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ndt\/gfu015","volume":"30","author":"M Burnier","year":"2015","unstructured":"Burnier M, Pruijm M, Wuerzner G, Santschi V. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transpl. 2015;30(1):39\u201344.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"221_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/01.mnh.0000444912.40418.45","volume":"23","author":"MR Weir","year":"2014","unstructured":"Weir MR, Fink JC. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2014;23(3):306\u201313.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"221_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.mayocp.2015.01.016","volume":"90","author":"C Ponticelli","year":"2015","unstructured":"Ponticelli C, Sala G, Glassock RJ. Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician. Mayo Clin Proc. 2015;90(5):633\u201345.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"221_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00228-011-1163-8","volume":"68","author":"H Molanaei","year":"2012","unstructured":"Molanaei H, Stenvinkel P, Qureshi AR, Carrero JJ, Heimburger O, Lindholm B, et al. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. Eur J Clin Pharmacol. 2012;68(5):571\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"221_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10408449209145319","volume":"22","author":"SA Wrighton","year":"1992","unstructured":"Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1\u201321.","journal-title":"Crit Rev Toxicol"},{"issue":"1","key":"221_CR14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270(1):414\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"221_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687\u201393.","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"221_CR16","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1158\/1078-0432.CCR-06-0023","volume":"12","author":"KA Charles","year":"2006","unstructured":"Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492\u20137.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"221_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJM197812282992604","volume":"299","author":"KM Piafsky","year":"1978","unstructured":"Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. New Engl J Med. 1978;299(26):1435\u20139.","journal-title":"New Engl J Med"},{"issue":"4","key":"221_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2133\/dmpk.DMPK-13-SH-138","volume":"29","author":"L Bj\u00f6rkhem-Bergman","year":"2014","unstructured":"Bj\u00f6rkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson TB, et al. Quinine compared to 4beta-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin. Drug Metab Pharmacokinet. 2014;29(4):352\u20135.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"42","key":"221_CR19","doi-asserted-by":"publisher","first-page":"38685","DOI":"10.1074\/jbc.M105127200","volume":"276","author":"K Bodin","year":"2001","unstructured":"Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem. 2001;276(42):38685\u20139.","journal-title":"J Biol Chem"},{"issue":"2","key":"221_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","volume":"71","author":"U Diczfalusy","year":"2011","unstructured":"Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4beta-hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans. Br J Clin Pharmacol. 2011;71(2):183\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"1 Suppl","key":"221_CR21","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/0091270011413588","volume":"52","author":"J Naud","year":"2012","unstructured":"Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharm. 2012;52(1 Suppl):10S\u201322S.","journal-title":"J Clin Pharm"},{"issue":"8","key":"221_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","volume":"10","author":"TJ Velenosi","year":"2014","unstructured":"Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014;10(8):1131\u201343.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"221_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757\u201373.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"221_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/gut.32.7.754","volume":"32","author":"M Magnusson","year":"1991","unstructured":"Magnusson M, Magnusson KE, Sundqvist T, Denneberg T. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut. 1991;32(7):754\u20139.","journal-title":"Gut"},{"issue":"8","key":"221_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"221_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1046\/j.1525-139x.2000.00110.x","volume":"13","author":"TI Steinman","year":"2000","unstructured":"Steinman TI. Serum albumin: its significance in patients with ESRD. Semin Dial. 2000;13(6):404\u20138.","journal-title":"Semin Dial"},{"issue":"6","key":"221_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089\u201396.","journal-title":"Clin J Am Soc Nephrol"},{"key":"221_CR28","volume-title":"Dialysis of drugs: LLC, saline Michigan USA","year":"2013","unstructured":"Baillie G, Mason N, editors. Dialysis of drugs: LLC, saline Michigan USA 2013."},{"issue":"9","key":"221_CR29","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1681\/ASN.2006060610","volume":"17","author":"TD Nolin","year":"2006","unstructured":"Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17(9):2363\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"221_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1254\/jphs.08042FP","volume":"108","author":"J Michaud","year":"2008","unstructured":"Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharm Sci. 2008;108(2):157\u201363.","journal-title":"J Pharm Sci"},{"issue":"1","key":"221_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpt.128","volume":"98","author":"DE Coutant","year":"2015","unstructured":"Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, et al. Understanding disease-drug interactions in Cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther. 2015;98(1):76\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"221_CR32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1053\/j.ajkd.2009.02.008","volume":"53","author":"S Snaedal","year":"2009","unstructured":"Snaedal S, Heimburger O, Qureshi AR, Danielsson A, Wikstrom B, Fellstrom B, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kid Dis. 2009;53(6):1024\u201333.","journal-title":"Am J Kid Dis"},{"issue":"2","key":"221_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.12441","volume":"79","author":"RR Shah","year":"2015","unstructured":"Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clinical Pharm. 2015;79(2):222\u201340.","journal-title":"Br J Clinical Pharm"},{"issue":"3","key":"221_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1124\/dmd.114.061093","volume":"43","author":"RR Shah","year":"2015","unstructured":"Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"221_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063493","volume":"8","author":"A Witasp","year":"2013","unstructured":"Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Naslund E, et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8(5):e63493.","journal-title":"PLoS One"},{"issue":"1","key":"221_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","volume":"67","author":"U Diczfalusy","year":"2009","unstructured":"Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, Bertilsson L. 4beta-hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clinical Pharm. 2009;67(1):38\u201343.","journal-title":"Br J Clinical Pharm"},{"issue":"5","key":"221_CR37","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie\u201d. Drug Metab Dispos. 2006;34(5):880\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"221_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clpt.2004.07.001","volume":"76","author":"J Yang","year":"2004","unstructured":"Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther. 2004;76(4):391.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"221_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.25.28","volume":"25","author":"A Galetin","year":"2010","unstructured":"Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet. 2010;25(1):28\u201347.","journal-title":"Drug Metab Pharmacokinet"},{"key":"221_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/854015","volume":"2015","author":"L Basheer","year":"2015","unstructured":"Basheer L, Kerem Z. Interactions between CYP3A4 and dietary polyphenols. Oxidative Med Cell Longev. 2015;2015:854015.","journal-title":"Oxidative Med Cell Longev"},{"issue":"4","key":"221_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/ASN.2013080905","volume":"25","author":"A Ramezani","year":"2014","unstructured":"Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"221_CR42","doi-asserted-by":"publisher","unstructured":"Bezirtzoglou EE. Intestinal cytochromes P450 regulating the intestinal microbiota and its probiotic profile. Microb Ecol Health Dis. 2012;23. https:\/\/doi.org\/10.3402\/mehd.v23i0.18370 .","DOI":"10.3402\/mehd.v23i0.18370"},{"issue":"3","key":"221_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","volume":"18","author":"U Diczfalusy","year":"2008","unstructured":"Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008;18(3):201\u20138.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"221_CR44","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1124\/dmd.113.051698","volume":"41","author":"L Bj\u00f6rkhem-Bergman","year":"2013","unstructured":"Bj\u00f6rkhem-Bergman L, Bergstrom H, Johansson M, Parini P, Eriksson M, Rane A, et al. Atorvastatin treatment induces uptake and efflux transporters in human liver. Drug Metab Dispos. 2013;41(9):1610\u20135.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"221_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/bcpt.12537","volume":"118","author":"L Bj\u00f6rkhem-Bergman","year":"2016","unstructured":"Bj\u00f6rkhem-Bergman L, Nylen H, Eriksson M, Parini P, Diczfalusy U. Effect of statin treatment on plasma 4beta-hydroxycholesterol concentrations. Basic Clin Pharmacol Toxicol. 2016;118(6):499\u2013502.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"221_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1055\/s-2007-999171","volume":"12","author":"GO Perez","year":"1980","unstructured":"Perez GO, Hsia SL, Christakis G, Burr J. Serum cholesterol binding reserve and high density lipoprotein cholesterol in patients on maintenance hemodialysis. Horm Metab Res. 1980;12(9):449\u201354.","journal-title":"Horm Metab Res"},{"key":"221_CR47","first-page":"31","volume":"i561","author":"H Molanaei","year":"2016","unstructured":"Molanaei H, Qureshi AR, Heimb\u00fcrger O, Lindholm L, Diczfalusy U, Anderstam B, et al. Inflammation down regulates cytochrome P450 mediated drug metabolism in hemodialysis patients. Nephrol Dial Transpl. 2016;i561:31.","journal-title":"Nephrol Dial Transpl"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:54:40Z","timestamp":1751691280000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0221-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"17 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed at the Karolinska University Hospital, Stockholm, Sweden. The Ethics Committee of Karolinska Institutet, Stockholm approved the study. All the participants in the study gave their written informed consent following verbal and written information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Bengt Lindholm is employed by Baxter Healthcare Corporation. None of the other authors declare any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"33"}}